Jump to content

All Activity

This stream auto-updates     

  1. Yesterday
  2. Thanks. They are not helpful. That is the timeframe that we are stuck with for specimen expiration.
  3. Does anyone out there have a revalidation plan for Scheduled LIS downtime for hours? What kind of tests do you do once the LIS comes back to make sure things are working as they are supposed to? thanks,
  4. Can leuko-reduce prevent GVHD

    Right. So leukoreduction helps prevent those pesky febrile transfusion reactions, and irradiation helps prevent GVHD. They are not the same thing, after all! Scott
  5. Linearity on Inform II

    I don't routinely perform linearity on our glucometers since it is a waived instrument and linearity on new meters is not required per the manufacturer. We use Nova StatStrip meters.
  6. What is the prevailing thought regarding the quality of platelet products stored with bubbles or foam? I found two articles that concluded that "storage with air bubbles/foam causes considerable enhancement of disintegration of platelets".
  7. Linearity on Inform II

    every six months
  8. Criteria for Pathology Review

    We have an actual form the techs need to fill out that includes the criteria set by our hematopathologist. I've (hopefully) attached it here.... SMEAR REQUEST FORM.docx
  9. Last week
  10. Analyzer updates?

    We went LIVE with the Erytra just over a year ago. Have had some "kinks" to work out, but as others have indicated, Grifols is GREAT at responding to fixes and corrections! I am totally a GEL girl.....and the Vision has had some issues of it's own. The Erytra and Grifols have a great future.....that I feel confident of. It is a fun machine to operate and is definitely advantageous in many ways....especially for large Institutions. Brenda Hutson, MT(ASCP)SBB
  11. How often does everyone do linearity testing on their glucometers, specifically the Inform II?
  12. V1 x C1 = V2 x C2 where V1 is volume of initial unit in mL, C1 = hematocrit (%) of initial unit, C2 = desired hematocrit (%), and V2 = final volume in mL V1 - V2 = volume of plasma to remove in mL 1.06 g/mL is approximate specific gravity of whole blood. You will need to subtract the tare weight of empty collection bag and convert weight to volume using specific gravity.
  13. Can leuko-reduce prevent GVHD

    This also makes you wonder - still - if all of these studies on Patient Blood Management today were really done on patients with 100% leukoreduced blood products - especially the studies done in the US. It is not always listed in the controlled study parameters. Also - if my memory has not faded completely(!) - I seem to remember leukocyte reduction being touted to decrease the same problems they are now after us to just "not give blood" for - the reasons so well detailed above. We have been on 100% leukocyte reduced RBCs here (from our blood supplier - Blood Systems, Inc) for a couple of decades now - and we see VERY few transfusion reactions. While that is not the only reason not to give blood - why are the posited post transfusion complications still the same? Did leukoreduction not work? Or are we still fighting the same complications because some of the US still has not adopted universal leukocyte reduction? Leukocyte reduction seems to have helped our patients a lot. Just curious -
  14. Monoclonal Control

    We use monoclonal control and use 1 drop of Anti-D and 1 drop of Monoclonal control.
  15. Can leuko-reduce prevent GVHD

    Sadly Neil, since that paper, and after many years with no TA-GvHD reported to SHOT, there has been just such a case in the last couple of years.
  16. Monoclonal Control

    The package insert for the control says to use the same test method that is used for the reagent being 'controlled'. If you use 2 drops of anti-D, you should use 2 drops of control.
  17. Can leuko-reduce prevent GVHD

    While I would not use leukoreduction as the primary method of preventing transfusion associated graft versus host disease in high risk patients, there is evidence that it reduces the incidence of this complication in patients not conventionally thought to be immunosuppressed. These data are from the UK haemovigilance reports. Lymphocytes are not killed by irradiation, but they cannot successfully proliferate, which is necessary for graft versus host disease to occur. These UK data make one wonder what the heck the USA experts (AABB and FDA) are thinking in not mandating universal leukoreduction 20 years after it was implemented in France, UK, Canada, etc. So little cost, so many benefits. Three FDA committees have voted overwhelmingly that universal leukoreduction is clinically sound policy. No action. Many pleas to the AABB. No action. This is one of the most cost-effective and important innovations in transfusion safety in the last half century. It reduces suffering, morbidity and mortality. It's cheap and easy. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, Lucas G, Beatty C, Casbard A, Cohen H. Transfusion. 2007 Aug;47(8):1455-67.
  18. Can leuko-reduce prevent GVHD

    To quote from a journal article: "Removal of leucocytes from various blood products has been shown to minimize Febrile nonhemolytic transfusion reactions, HLA alloimmunization, platelet refractoriness in multitransfused patients and prevention of transmission of leukotropic viruses such as EBV and CMV." Irradiation does not remove or inactivate the antigens that cause these problems.
  19. Can leuko-reduce prevent GVHD

    Irradiation does not "kill" T lymphocytes per se, which are the cells that cause TA-GvHD, but what it does is disrupt the DNA within the nucleus, and this disruption prevents them from cloning. As a result, they are unable to "reproduce" (for want of a better way of putting it) and so, instead of being able to form a clone within the recipient, will be removed from the circulation by natural apoptosis. Prior to this apoptosis, once they have been irradiated, the T lymphocytes are relatively benign.
  20. A2B pacient transfusion policy

    As long as the anti-A1 remains "cold reacting" only, and the thermal amplitude does not widen, the clinical significance remains as "not clinically significant", and, personally, I would happily transfuse blood by electronic issue. Even if the thermal amplitude does widen, unless the anti-A1 actually reacts at strictly 37oC, it will remain as "not clinically significant", but I would, nevertheless, perform a serological cross-match - "just as belt and braces".
  21. Can leuko-reduce prevent GVHD

    I guess irradiation can inactivate the lymphocytes, but not deprave the antigens it takes, so it can not replace leukoreduction.
  22. A2B pacient transfusion policy

    We have a liver transplant patient AsubB with an anti-a1 (cold). Our computer allows electronic "XM". Do you agree with this or recommend a serologic XM?
  23. Can leuko-reduce prevent GVHD

    thanks but my question: can we irradiate cellular product instead of leukoreduction you said " you must kill all of the WBCs in the donor blood product. This is accomplished with radiation. " ?
  24. Can leuko-reduce prevent GVHD

    Leukoreduction, by no means that I know of, can get rid off ALL WBCs in a blood product. So if you are worried about Graft-Versus-Host Disease in an immunocomprimised patient, you do not want to rely on leukoreduction alone. The residual donor WBCs may "engraft" into the host recipient's system, and attack the recipient as a foreign threat. So to avoid GVHD, you must kill all of the WBCs in the donor blood product. This is accomplished with radiation. Scott
  25. CAP TRM. 40670

    All in fun!! I do appreciate the feedback as I need to address this at some point, like yesterday.
  26. Monoclonal Control

    Any one using Monoclonal Control (immucor reagent ) when performing weak D test or for AB Pos CORD. Are you using one drop or two drop of monoclonal control.
  1. Load more activity
  • Advertisement

×